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The prevalence of depression in end-stage renal disease
(ESRD) patients on hemodialysis has not been definitively
determined. We examined the prevalence of depression and
the sensitivity, specificity, positive, and negative likelihood
ratios (þ LR and LR) of self-report scales using the
physician-administered Structured Clinical Interview for
Depression (SCID) as the comparison. Ninety-eight
consecutive patients completed the Beck Depression
Inventory (BDI) and the Center for Epidemiological Study of
Depression (CESD) scales. A physician blinded to BDI and
CESD scores administered the SCID. Receiver/responder
operating characteristic curves determined the best BDI and
CESD cutoffs for depression. Depressed patients had more
co-morbidities and lower quality of life, Po0.05. The
prevalence of depression by SCID was 26.5% and of major
depression was 17.3%. The CESD cutoff with the best
diagnostic accuracy was 18, with sensitivity 69% (95%
confidence interval (CI) (51%, 87%)), specificity 83% (95% CI
(74%, 92%)), positive predictive value (PPV) 60%, negative
predictive value (NPV) 88%, þ LR 4.14, and –LR 0.37. The best
BDI cutoff was 14, with sensitivity 62% (95% CI (43%, 81%)),
specificity 81% (95% CI (72%, 90%)), PPV 53%, NPV 85%,
þ LR 3.26, and –LR 0.47. Self-report scales have high þ LR but
low LR for diagnosis of depression. When used for
screening, the threshold for depression should be higher for
ESRD compared with non-ESRD patients. Identifying
depression using physician interview is important, given the
low LR of self-report scales.
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Depressive symptoms are prevalent among patients with end-
stage renal disease (ESRD) treated with chronic hemodialysis
(HD), and there is growing evidence that these symptoms are
associated with increased mortality.1–5 A distinction must be
made between the presence of high levels of depressive affect
as reported by ESRD patients on self-administered depression
screening scales and a diagnosis of a depressive disorder as
defined by the Diagnostic and Statistical Manual of Mental
Disorders IV (DSM IV) criteria.6 ESRD patients may report
increased symptoms of fatigue, poor appetite, and sleep
disturbance on self-report depression scales that may not be
confirmed as a depressive disorder during a DSM IV-based
structured interview. There is a large literature using the Beck
Depression Inventory (BDI) as a screening tool for
identification of depressive symptoms among patients on
chronic dialysis,1,3,7,8 but diagnostic data regarding depressive
disorder are limited.
There is a paucity of information regarding the psycho-
metric properties of self-administered questionnaires such as
the BDI among ESRD samples.8 Specifically, self-report
depression scales may overemphasize the somatic symptoms
of depression and may, therefore, lead to misclassification of
symptoms of uremia and chronic disease for those of
depression.1,9 One study evaluated the BDI against the
Diagnostic Interview Schedule (DIS), for the diagnosis of
depression among an all-white ESRD sample, only 36% of
whom were being treated with HD.8 The DIS is a structured
interview for the diagnosis of depressive disorder that has
been validated against the DSM IV in non-ESRD popu-
lations.10 These findings were not validated in non-white
ESRD samples.8,11 The use of such self-report scales in
previous research also makes it difficult to accurately estimate
the prevalence of major depression in ESRD patients.1,12 The
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 18 February 2005; revised 24 October 2005; accepted 31
October 2005; published online 5 April 2006
Correspondence: SS Hedayati, VA North Texas Health Care System,
Nephrology Section, MC 111G1, 4500 South Lancaster Road, Dallas, Texas
75216-7167, USA. E-mail: susan.hedayati@med.va.gov
1662 Kidney International (2006) 69, 1662–1668
lack of data regarding the prevalence of depressive disorder
makes it hard to formulate sample size calculations for
designing future treatment studies of depression in ESRD
patients.
The purpose of our study was to investigate the prevalence
of depression in ESRD patients treated with chronic HD
using a DSM IV-validated psychiatric interview and to
explore the utility of self-report screening scales, such as the
BDI and the Center of Epidemiological Studies Depression
Scale (CESD), in these patients. The Structured Clinical
Interview for Depression (SCID), a DSM IV-based, well-
validated clinical tool for establishing the diagnosis of
depressive disorder, was used as the comparison to establish
the cutoff scores on these scales with the best sensitivity and
specificity, and to determine the positive and negative
likelihood ratios (þ LR and LR) of these cutoff scores.13,14
RESULTS
Baseline characteristics of cohort
Of 173 patients who were approached, seven patients were
not eligible (four could not speak English and three had no
health-care power of attorney). Of the 166 eligible, 101
agreed to sign consent. Three patients were excluded. One
withdrew from the study before filling in any questionnaires.
Another received a kidney transplant before evaluation with
the SCID. The third was hospitalized before the SCID could
be administered. The total sample available for analysis was
98 patients.
The mean age of the overall cohort was 57 (Table 1). In all,
45% were female, 14% white, and 38% had diabetes mellitus
as the etiology of ESRD. Approximately one-fourth were
receiving chronic dialysis at the Veterans Health Affairs
(subsequently referred to as veterans).
Comparison of cohort based on diagnosis of depression
The prevalence of depressive disorder by SCID was 26.7%.
The prevalence of depression in the subgroup of veterans was
30.8%. Of the 26 patients depressed by SCID, 65% had major
depression, 27% dysthymia, and 8% minor depression. There
were no patients who had suicidal ideation. Fifty-four
percent (14 of 26) had a prior history of depression recorded
in their medical charts. Only 42% (11 of 26) had anti-
depressants prescribed. Of those for whom antidepressants
were prescribed, 45% (5 of 11) were on minimum doses.
Intervention was made in the case of only 23% (6 of 26) of
patients diagnosed with depressive disorder.
Baseline characteristics were not statistically different
among groups based on the presence or absence of
depression by SCID (Table 2). Patients who were depressed,
however, had a higher cumulative number of co-morbidities
than those who were not depressed (4.272.2 vs 2.971.6 for
depressed vs non-depressed, respectively, P-value 0.02).
There were no statistically significant differences between
dialysis processes of care, such as dialysis shift, vascular acc-
ess type, treatment time or dialysis adequacy (Table 3).
Patients with depression had lower predialysis systolic blood
pressures than those without depression (143.3721.3 vs
146.3718.7 mm Hg, P-value 0.05). No statistically significant
differences in mean hemoglobin and serum albumin
concentrations, measures of adherence to diet (such as serum
phosphorus and potassium concentrations), adherence to
interdialytic weight gain or adherence to dialysis prescription
(as measured by the number of missed dialysis sessions not
due to hospitalizations) could be observed in this cohort
based on the presence or absence of depression (Table 4).
Patients who were depressed by SCID had higher mean
BDI and CESD scores compared to those not depressed
(mean score for BDI 16.678.4 vs 9.176.2 and for CESD
24.179.8 vs 11.878.0 for depressed vs non-depressed,
respectively, P-value 0.0001 for both comparisons) (Table 5).
Mean number of errors on the Short Portable Mental
Status Questionnaire was similar between the two groups, in
the range of intact intellectual functioning (Table 5).
Depressed patients had lower mean scores on the Feinstein,
signifying lower self-rated quality of life (mean score on a
scale of 1–10 was 5.271.9 for depressed vs 7.572.1 for
nondepressed, P-value 0.0001).
Comparison of self-report measures of depression with SCID
In logistic regression models, the odds of depressive disorder
determined by SCID was 15% higher for each unit increase in
BDI (odds ratio 1.15, 95% confidence interval (CI) (1.07,
1.24)), and 16% higher for each unit increase in CESD (odds
ratio 1.16, 95% CI (1.08, 1.23)). The results were similar for
Cognitive Depression Inventory (CDI) (odds ratio 1.16, 95%
CI (1.06, 1.26)). In these models, the area under the curve
(AUC) for BDI, CESD, and CDI were 0.77, 0.86, and 0.76,
respectively.
Figures 1 and 2 illustrate the receiver/responder operating
characteristic curves used to derive the best cutoff scores on
BDI and CESD for depression. The CESD cutoff with the best
Table 1 | Baseline characteristics of entire cohort (n=98)
Characteristic Percent (7s.d.)
VA vs non-VA dialysis unit 26.5








Years on dialysis 4.1 (3.8)
DM as cause of ESRD 38.2
Total co-morbidity 3.3 (1.8)
Mean potassium (mmol/l) 4.9 (0.8)
Mean phosphorus (mg/dl) 6.0 (1.8)
Mean albumin (g/dl) 3.7 (0.4)
Mean Hgb (g/dl) 11.9 (1.4)
DM, diabetes mellitus; ESRD, end-stage renal disease; Hgb, hemoglobin; s.d.,
standard deviation; VA, veteran affairs.
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diagnostic accuracy (proportion of patients correctly classi-
fied by CESD as depressed or not depressed as compared with
SCID) was 18. When compared with SCID, this cutoff had a
sensitivity of 69%, 95% CI (51%, 87%), specificity of 83%,
95% CI (74%, 92%), positive predictive value (PPV) of 60%,
negative predictive value (NPV) of 88%, and diagnostic
accuracy of 80%. The agreement between this CESD cutoff
and SCID was moderate, Kappa statistic 0.50, P-value
o0.0001.
The BDI cutoff with the best diagnostic accuracy was 14,
with a sensitivity of 62%, 95% CI (43%, 81%), specificity of
81%, 95% CI (72%, 90%), PPV of 53%, NPV of 85%, and
diagnostic accuracy of 76%. The agreement between this BDI
cutoff and SCID was lower than that between CESD and
SCID, Kappa statistic 0.40, P-value o0.0001. The cutoff with
the best diagnostic accuracy on the CDI was 8. Sensitivity,
specificity, PPV, and NPV were 50%, 83%, 52%, and 82%,
respectively. The agreement with SCID was lowest for CDI
with Kappa statistic 0.34, P-value 0.0008.
Two-by-two tables are presented for the optimal cutoff
scores on BDI and CESD vs SCID diagnosis (Tables 6 and 7).
The þ LR for CESD cutoff of 18 was 4.14 and the LR was
0.37. The þ LR and –LR for the BDI cutoff of 14 were 3.26
and 0.47, respectively.
DISCUSSION
In this study, we blindly assessed the prevalence of a
psychiatric diagnosis of depression using the structured,
validated physician-administered interview, SCID, in a
consecutive sample of dialysis patients. It is one of the first
studies to investigate the screening characteristics of self-
report measures of depression, such as the BDI and CESD, by
comparison to the validated ‘gold standard’ SCID.
Table 2 | Baseline characteristics of patients by the presence







Durham VA 69.2 30.8 NS
Duke Site 1 77.3 22.7
Duke Site 2 74.0 26.0
Mean age 57.6 (14.5) 56.4 (12.0) NS
Female gender 44.4 46.2 NS




Married 33.3 44.0 NS
Lives alone 36.1 23.1 NS
Employed 11.1 19.2 NS
Transplant list 45.1 46.1 NS
DM caused ESRD 36.1 44.0 NS
Years on dialysis 4.1 (3.7) 4.1 (3.9) NS
Total co-
morbidity
2.9 (1.6) 4.2 (2.2) 0.02
DM, diabetes mellitus; ESRD, end-stage renal disease; NS, non-significant; SCID,
Structured Clinical Interview for Depression; s.d., standard deviation; VA, veterans
affairs.







1 54.9 44.2 NS
2 33.8 46.1
3 11.3 7.7
Endogenous fistula 41.7 30.8 NS
Prosthetic graft 31.9 50.0
Catheter 26.4 19.2
Treatment time (h) 3.4 (0.4) 3.5 (0.4) NS
Mean Kt/V 1.8 (1.1) 1.7 (1.2) NS
Kt/Vo1.2 15.1 8.7 NS
Mean URR 68.4 (6.2) 69.2 (6.3) NS
URRo65% 26.4 16.0 NS
Epo dose (U/kg) 97.4 (89.9) 102.3 (58.7) NS
Dry weight (kg) 81.2 (20.3) 85.4 (21.6) NS
Mean predialysis SBP
(mmHg)
146.3 (18.7) 143.3 (21.3) 0.05
Mean predialysis DBP 83.7 (12.7) 79.3 (14.8) NS
Mean postdialysis SBP 137.6 (19.3) 129.1 (21.5) NS
Mean postdialysis DBP 78.9 (11.6) 76.1 (16.5) NS
Mean nadir intradialytic
SBP
126.2 (18.9) 119.3 (23.7) NS
Mean predialysis PP 62.6 (14.0) 64.0 (16.1) NS
Mean postdialysis PP 58.7 (15.0) 53.0 (19.0) NS
DBP, diastolic blood pressure; PP, pulse pressure; SBP, systolic blood pressure; s.d.,
standard deviation; URR, urea reduction ratio.







Missed HD not due to
hospitalization
38.1 36.4 NS
Interdialytic wt gain (kg/kg
dry wt)
0.04 (0.02) 0.03 (0.01) NS
Mean potassium (mmol/l) 4.9 (0.7) 4.9 (0.9) NS
Mean phosphorus (mg/dl) 5.9 (1.8) 6.1 (1.7) NS
Mean albumin (g/dl) 3.8 (0.4) 3.7 (0.4) NS
Mean Hgb (g/dl) 11.9 (1.5) 11.9 (1.3) NS
Hgbo11 (g/dl) 19.4 23.1 NS
Mean calcium (mg/dl) 9.2 (0.7) 9.0 (0.5) NS
Mean intact PTH (pg/ml) 373.1 (484.7) 376.8 (310.3) NS
HD, hemodialysis; Hgb, hemoglobin; PTH, parathyroid hormone; s.d., standard
deviation.
Table 5 | Measures of depression, mental status, and






Mean BDI 9.1 (6.2) 16.6 (8.4) 0.0001
Mean CESD 11.8 (8.0) 24.1 (9.8) 0.0001
Mean SPMSQ 0.3 (0.7) 0.4 (0.9) NS
Mean
Feinstein
7.5 (2.1) 5.2 (1.9) 0.0001
BDI, Beck Depression Inventory Score; CESD, Center of Epidemiological Studies
Depression Scale Score; Feinstein, Feinstein Quality of Life Scale score; NS, non-
significant; s.d., standard deviation; SPMSQ, Short Portable Mental Status
Questionnaire score.
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The prevalence of a depressive disorder using SCID was
26.5%, and the prevalence of major depression was 17.3%.
Previous studies reported prevalence of abnormal depressive
affect to be anywhere from 0 to 100%1,3,4,7,8,12,15,16 in ESRD
samples. The lack of consistency in these reports likely
reflects different disease severity, populations assessed at
different time-points since the introduction of chronic
dialysis and use of different depression measures.
Lack of consistent estimates may also reflect the different
baseline characteristics of the population sampled. Although
our study sample had a similar proportion of females and
diabetics as the prevalent ESRD US population, a signifi-
cantly higher proportion was African American.11 Given that
African Americans continue to have the highest prevalent
rates of ESRD,11 and that depression has been noted to be a
salient problem for African Americans in the general
population17 as well as among ESRD patients,18 it is
important that African Americans be represented uniformly
in any ongoing studies investigating disease prevalence. In
addition, our findings in a predominantly African American
sample confirm those of an earlier all-white study using the
BDI.8
In addition to examining the prevalence of depression, our
study established the screening characteristics of the BDI,
CESD, and CDI self-report scales against the SCID interview.
The cutoff score with the best diagnostic accuracy for the
diagnosis of depression was X14 for the BDI in our study
using the SCID as the comparator, and X15 in the Craven
study using the DIS, both higher than the cutoff of X10
validated in the general, non-ESRD population.19 The
similarity of cutoffs in the two studies in different popula-
tions in different eras bolsters our findings.
The cutoff with the best diagnostic accuracy for the CESD
in our study was also higher than that validated in non-ESRD
samples.20 The higher thresholds for the diagnosis of
depression in ESRD support the hypothesis that self-
administered scales may elicit positive responses to somatic
depressive symptoms that a structured interview may not
confirm as associated with a depressive disorder. Such
symptoms, such as sleep disturbance, changes in appetite
and weight, and fatigue, may co-exist with symptoms of
uremia and chronic disease that are common in chronic
dialysis patients.1,15 We, however, could not confirm that a
cognitive subset of the BDI, the CDI, had better diagnostic
accuracy in this sample after somatic symptoms were
excluded. The additional 2% that was gained by CDI over
BDI in specificity was counteracted by the much lower
sensitivity of CDI for screening depression (50% for CDI vs
62%). The agreement with SCID was also lower for CDI
when compared with BDI (Kappa statistic 0.34 vs 0.40).
When evaluating a screening test against a diagnostic ‘gold
standard’, it is important to emphasize the significance of
LRs, measures that, unlike the PPV and NPV, do not depend
on the prevalence of disease, and take into account all four
cells of the two-by-two table. The LRs express the odds that a
given cutoff of the screening test would be expected in a
patient with depression (as opposed to one without
depression).21 Knowing the pretest probability of depression
in a given patient, one could use the LRs to predict the post-
test probability of depression in that patient based on their
score on the test. For example, based on the þ LR of 4.14 for
CESD cutoff of 18, for a population with a prevalence of
depression of 26.5%, the probability of depression in a
















Cutoff 16, sens 73%, spec 76%
Cutoff 17, sens 73%, spec 81%
Cutoff 18, sens 69%, spec 83%
0.0139 0.2111 0.4083 0.6056 0.8028 1.0000
0.90140.70420.50690.30970.1125
1– specificity
















ity Cutoff 12, sens 65%, spec 72%
Cutoff 11, sens 69%, spec 67%
Cutoff 14, sens 62%, spec 81%
Cutoff 15, sens 50%, spec 83%
0.0139 0.2111 0.4083 0.6056 0.8028 1.0000
0.90140.70420.50690.30970.1125
1– specificity
Figure 2 | Receiver/responder operating characteristic (ROC)
curve for BDI.
Table 6 | Two-by-two table of CESD vs SCID diagnosis
SCID (+) SCID () Total
CESDX18 18 12 30
CESDo18 8 60 68
Total 26 72 98
CESD, Center for Epidemiological Study of Depression; SCID, Structured Clinical
Interview for Depression. SCID (+) represents number of patients who had
depression by SCID; SCID () represents number of patients who had no depression
by SCID.
Table 7 | Two-by-two table of BDI vs SCID diagnosis
SCID (+) SCID () Total
BDIX14 16 14 30
BDIo14 10 58 68
Total 26 72 98
Abbreviations: BDI, Beck Depression Inventory; SCID, Structured Clinical Interview
for Depression.
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26.5%). The probability of depression would decrease from
26.5 to 12% for a patient with a score o18.
The CESD not only had a higher þ LR and a lower –LR
than the BDI, but also a higher AUC, which is an index of
‘goodness’ of the test. Although these data may suggest that
the CESD, as compared with the BDI, is a more accurate
screening tool in ESRD patients, further research using larger
samples is needed to confirm these results.
Additional findings that patients with depression have a
higher number of co-morbidities and lower self-reported
quality of life also confirm previous reports.7,22–30 There is
more evidence in the cardiovascular than renal literature
supporting a relationship between depression and co-
morbidity.27–31 These data raise the possibility that the
higher rates of morbidity and mortality found in depressed
patients may be, in part, secondary to higher levels of co-
morbidity.27 Further studies are needed to determine whether
a physician diagnosis of depression predicts poor outcomes
independent of co-morbidity in ESRD patients.
Finally, the low rate of treatment for depression present in
this sample is noteworthy. Less than half of patients who were
found to be depressed by SCID were being treated with
antidepressants, and about half of those were on what could
be considered subtherapeutic doses in patients without renal
failure. Low treatment rates were reported previously, where
BDI scoreX15 was used to define depression.7 Even after the
diagnosis of depression was confirmed using SCID, inter-
vention was only made in less than one-fourth of patients. It
is recognized that the measure of intervention may not have
accurately reflected physician intent to treat depression, since
patients may have declined treatment. Furthermore, the role
of therapy is unknown not only in patients with increased
levels of depressive affect in the absence of major depression,6
but also in ESRD patients with an established diagnosis of
depression.1,3,15,32,33 There is not enough evidence to clearly
suggest that treatment of major depression changes clinical
outcomes in ESRD patients.32,33 Additional research is
needed to establish the safety and efficacy of the use of
antidepressants in patients treated with chronic dialysis.
The study has several limitations that warrant discussion.
Since sample size must be taken into consideration, failure to
have found an association between certain patient character-
istics, such as serum albumin concentration and measures of
adherence, with depression does not mean that an association
did not exist. Clinical correlates of depression should be
examined in larger samples. Another limitation is the
potential bias introduced by the unavoidable percentage of
non-participants, as has been a limitation of several previous
studies of depression in ESRD patients.4,8,33 This bias was,
however, minimized in our study by the consecutive manner
in which patients were recruited. Lastly, although the high
percentage of African Americans may focus this study’s
generalizability based on race, findings similar to that of an
earlier all-white study add to the limited body of literature
that exists on this subject. Future larger studies are needed to
validate these results.
In conclusion, the prevalence of a depressive disorder
among ESRD patients treated with HD is high when a
structured, physician-administered interview is used for
diagnosis. Self-report questionnaires do not perform well as
diagnostic tools for depression at any cutoff, with kappa
values for agreement with the SCID in the moderate range at
best. Both the BDI and CESD, however, had high þ LR at the
proposed cutoffs, which makes them acceptable screening
tools.
Given the increasing demands on clinical nephrologists to
diagnose and treat medical co-morbidities in the progres-
sively aging dialysis population, these scales may serve as
screening tools to identify patients at high risk for clinical
depression. Based on the high prevalence of depression and
previous literature that suggests that depression may be
associated with poor outcomes, we recommend that ESRD
patients be screened with either the BDI or CESD at
initiation of dialysis and again within the first year, perhaps
at 6 months after initiation, and then yearly. Those who
screen positive should undergo a structured psychiatric
interview or be referred to a psychiatrist to confirm the
presence of depressive disorder. Based on our findings, we do
not recommend using the CDI for screening given that it has
low sensitivity and may miss patients who might be other-
wise classified as depressed if a formal interview were used.
The distinction between high levels of depressive affect
and the psychiatric diagnosis of depression is critical both for
patient care and for the design of clinical trials. The use of
structured psychiatric interviews for the diagnosis of
depression in this chronically ill population is important,
since the psychiatric diagnosis as well as the level of
depressive affect may be associated with differential mortal-
ity.1,3,4,9,15 This becomes especially pertinent in any future
intervention trials designed to examine the efficacy and safety
of antidepressants in this population. Well-designed inter-
ventions based on valid clinical data may prove powerful
methods to improve the quality and quantity of life for ESRD
patients treated with dialysis.
MATERIALS AND METHODS
Participants
We performed a prospective cohort study of patients with ESRD
treated with chronic HD at the Durham Veterans Health Affairs, and
two other units affiliated with Duke University Medical Center.
Patients were enrolled from March 2003 to April 2004. All English-
speaking patients who had health-care power of attorney and could
sign consent were eligible. The institutional review boards at both
the Durham Veterans Health Affairs and Duke University approved
the study. Patient names were alphabetized by shift of dialysis, and
each patient was invited individually and consecutively by
alphabetical order to participate.
Measures of depression
The research assistant administered all of the self-report measures to
patients at enrollment, including the 10-item validated Short
Portable Mental Status Questionnaire to identify dementia,34
the BDI, the CESD, and the Feinstein Scale. The BDI, a 21-item
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self-administered questionnaire, was shown to be a sensitive
screening tool for depression, as well as a clinically useful scale for
measuring the severity of depressive affect in both general and ESRD
populations.8,15,19,35 The score can range from 0 to 63, and a score of
X10 is the originally defined cutoff for depression in the general
population.19 The CESD is a 20-item Likert scale, with scores
ranging from 0 to 60. Patients with a score of 16 or higher are
considered at risk for depression in the general population.20 Global
quality of life was assessed by the Feinstein Scale, a self-rated one-
item scale that asks the patient to assess his or her overall quality of
life.22 The score ranges from 0 to 10 (very bad to excellent). It was
previously used in patients treated with chronic HD, and shown to
correlate with depression, life satisfaction, perception of burden of
illness, social support, and satisfaction with nephrologist scores.22
The SCID was administered within a week of the other
questionnaires to all patients13 by the same nephrologist, who was
blinded to patient medical history and scores on all questionnaires.
The SCID is a frequently used semistructured clinical interview for
the diagnosis of depression based on DSM IV criteria, and has
established reliability and validity.14,36,37 The SCID was used as the
comparison for diagnosis of depression, based on which the
sensitivities, specificities, positive, and negative LRs of BDI and
CESD as screening tools could be evaluated.
If a patient met the modified DSM IV criteria for depression or
indicated any suicidal ideation, it was reported to the patient’s
dialysis physician. Given the observational nature of the study,
intervention regarding depression was left to the discretion of the
patient’s physician. Medical records were searched to see whether
any intervention was initiated among patients diagnosed with
depression, within 4 weeks of evaluation. Intervention was defined
as referral to a mental health clinic, initiation of an antidepressant or
increasing the dose of a previously prescribed antidepressant.
Data collection
Demographic and clinical data were obtained from medical records
and confirmed with each patient in order to characterize the sample.
Clinical data included serum albumin, measures of dialysis
adequacy, and anemia. Medical co-morbidity included a history of
diabetes mellitus, hypertension, congestive heart failure, coronary
artery disease, cerebrovascular disease, peripheral vascular disease,
chronic lung disease, cancer (excluding skin), HIV disease, chronic
pain, psychiatric illness, illicit drug or alcohol abuse, and current
tobacco abuse. Measures of adherence included monthly predialysis
serum potassium and phosphorus concentrations, interdialytic
weight gain (which was calculated as the average of the most recent
six predialysis weights minus established dry weight, divided by dry
weight),38 and dialysis adherence (which was measured as the
number of missed dialysis sessions not due to hospitalization in the
previous 2 months).39 Pre- and post-HD systolic and diastolic blood
pressures, pulse pressure, and lowest intradialytic systolic blood
pressure were recorded at enrollment.
Statistical analysis
Participants were classified as cases or non-cases of depression,
including dysthymia, minor or major depression, on the basis of
their SCID diagnosis. Demographic and clinical characteristics were
compared among cases vs non-cases using the w2 test for categorical
and Student’s t-test for continuous variables. For repeated measures,
the means of the values of the most recent six HD sessions were
used. Serum albumin concentrations that were measured using the
bromcresol purple method were converted mathematically to a
value consistent with the bromcresol green method by adding
0.55.40 Urea reduction ratio was calculated by the following formula:
((predialysis serum blood urea nitrogen (BUN)postdialysis serum
BUN)/predialysis serum BUN) 100.41 The second-generation
single-pool Daugirdas formula was used to calculate Kt/V.42
Cumulative medical co-morbidity score was defined as the sum of
the number of co-morbidities.
Logistic regression was used to examine the association of BDI
and CESD with the diagnosis of depression using SCID. The
performances of BDI and CESD were assessed by sensitivity (the
percentage of ‘true’ cases identified by the scale), specificity (the
percentage of ‘true’ non-cases), PPV (the proportion of patients
with a positive scale result who are depressed), and NPV (the
proportion of patients with a negative scale result who are not
depressed) using the SCID as the comparison.21 Receiver/responder
operating characteristic curves and plots of sensitivity against
1specificity at different scale cutoffs were used to identify optimal
cutoff scores. The optimal cutoff score is the point when an increase
in sensitivity is associated with a significant drop in specificity.43 The
AUC was calculated to estimate each scale’s overall accuracy. The
ideal scale would have an AUC of 1.0, with a sensitivity and
specificity each of 100%, whereas an AUC of 0.5 would indicate a
likely random relationship between the scale and the gold standard.
Positive and negative LRs were also calculated for each of the cutoff
scores. Kappa statistic was used to estimate the agreement between
the optimal cutoff score on BDI and CESD vs SCID.
We also analyzed the first 15 items of BDI, referred to as the CDI
in comparison to the SCID. This is the ‘non-somatic’ subscale of the
BDI and has been used in ESRD patients by Kimmel in order to
investigate whether it is a more specific scale for depression.1,2,3
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